Zavante Therapeutics

Developing novel therapies to improve the outcomes of hospitalized patients

Zavante Therapeutics is a clinical late-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. The company's lead product candidate, ZTI-01, is a novel injectable antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains where current therapeutic choices are severely limited. Zavante's leadership team (including CEO Ted Schroeder and Chairman Cam Garner) was previously affiliated with Cadence Pharmaceuticals, which sold to Mallinckrodt in 2014.

Status
Acquired by Nabriva in 2018 (NASDAQ:NBRV)
Year of Investment
2016
Strategy
Life Sciences
Location
San Diego, California